title: Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer.
abstract: OBJECTIVE
  Ovarian carcinoma is the main cause of gynecological cancer related deaths. The aim of this study was to determine the activation status of the antioxidant response in samples of ovarian serous carcinoma from paraffin-embedded biopsies and compare them with the response of patients to carboplatin-paclitaxel treatment.
  
  
  METHODS
  Estrogen receptor alpha (ERα), antioxidant enzymes, and uncoupling protein (UCP) levels were analyzed by western blotting and the presence of estrogen receptor beta (ERβ) was investigated by immunohistochemistry (IHC).
  
  
  RESULTS
  Lower levels of ERα, antioxidant enzymes and UCPs were found in patients resistant to treatment in comparison to the carboplatin/paclitaxel-sensitive ones; IHC revealed a greater presence of ERβ in sensitive patients.
  
  
  CONCLUSIONS
  These results indicate that patients resistant to treatment have a lower level of antioxidant response activation compared to sensitive patients, fact which may be related to the efficacy of this treatment.
authors.affiliation: Multidisciplinar Group of Translational Oncology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Mallorca, Balearic Islands, Spain.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Pons
authors.forename: Jorge
authors.initials: J
authors.lastname: Sastre-Serra
authors.forename: Mercedes
authors.initials: M
authors.lastname: Nadal-Serrano
authors.forename: Aina
authors.initials: A
authors.lastname: Oliver
authors.forename: Magdalena
authors.initials: M
authors.lastname: García-Bonafé
authors.forename: Isabel
authors.initials: I
authors.lastname: Bover
authors.forename: Pilar
authors.initials: P
authors.lastname: Roca
authors.forename: Jordi
authors.initials: J
authors.lastname: Oliver
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D015153:Blotting, Western; D016190:Carboplatin / Q000494:pharmacology / Q000627:therapeutic use*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007473:Ion Channels / Q000378:metabolism; D024101:Mitochondrial Proteins / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use*; D000071256:Uncoupling Protein 1
chemical_list: D000975:Antioxidants; D047628:Estrogen Receptor alpha; D007473:Ion Channels; D024101:Mitochondrial Proteins; D000071256:Uncoupling Protein 1; D016190:Carboplatin; D017239:Paclitaxel